EXPRESSION OF ABC TRANSPORTERS AND CHANGES IN LYPHOCYTE SUBPOPULATIONS IN RESPONSE TO HYPERTHERMIC LIMB PERFUSION
COMBINED EFFECTS OF FRACTIONATION AND RADIOPROTECTANT IN SPARING OF RADIATION INDUCED PHYSEAL DAMAGE
SEQUENTIAL HISTOMORPHOMETRIC CHANGES IN SPRAGUE-DAWLEY RAT GROWTH PLATE FOLLOWING IRRADIATION
SUCCESSFUL PHASE II TRIAL OF ETOPOSIDE AND HIGH DOSE IFOSFAMIDE IN NEWLY DIAGNOSED METASTATIC OSTEOSARCOMA: AN UPDATE. A PEDIATRIC ONCOLOGY GROUP TRIAL (POG)
PRE-SURGICAL CHEMOTHERAPY VS IMMEDIATE SURGERY AND ADJUVANT CHEMOTHERAPY FOR NON-METASTATIC OSTEOSARCOMA. SURGICAL RESULTS OF POG 8651
INVESTIGATION OF GENETIC DETERMINANTS OF METASTATSIS IN A MURINE MODEL OF OSTEOSARCOMA WITH SPONTANEOUS METASTASIS USING cDNA MICRO-ARRAY
THE TREATMENT OF OSTEOSARCOMA OF THE EXTREMITIES WITH DETECTABLE LUNG METASTASES AT PRESENTATION: THE RIZZOLI EXPERIENCE ON 76 PATIENTS
IMAGING IN THE EVALUATION OF PRIMARY CHEMOTHERAPY IN EWING/PNET TUMORS. CORRELATION WITH NECROSIS AND SURVIVAL. AN ITALIAN SARCOMA GROUP/SCANDINAVIAN SARCOMA GROUP STUDY
THE ROLE OF MR IMAGING FOR FOLLOWING AGGRESSIVE AND MALIGNANT SOFT TISSUE TUMORS AFTER RESECTION, RADIATION THERAPY, AND CHEMOTHERAPY
OSTEOGENIC SARCOMA: ASSESSMENT OF TUMOR NECROSIS WITH DYNAMIC MR IMAGING AFTER NEOADJUVANT CHEMOTHERAPY - WORK IN PROGRESS
HISTOLOGIC RESPONSE OF HIGH GRADE SOFT TISSUE SARCOMAS TO INDUCTION CHEMOTHERAPY
TREATMENT AS INDUCED PATHOLOGIC NECROSIS AS A PREDICTOR OF SURVIVAL IN PATIENTS RECEIVING PRE-OPERATIVE THERAPY FOR EXTREMITY SOFT TISSUE SARCOMAS
REFINEMENT OF A COMMONLY DELETED SEGMENT OF CHROMOSOME ARM 18q IN 6-OSTEOSARCOMA
PHOSPHORILATION OF RB FAMILY GENES IN OSTEOSARCOMA PATIENTS: PATTERN OF EXPRESSION AND CORRELATION WITH OUTCOME
ANTIGENICITY OF FUSION PROTEINS FROM SARCOMA-ASSOCIATED CHROMOSOMAL TRANSLOCATIONS
EXPERIMENTAL STUDY ON THE INHIBITION EFFECT FOR LOCAL RECURRENCE AFTER INTRALESIONAL EXCISION OF OSTEOSARCOMA USING PHOTODYNAMIC THERAPY WITH ACRIDINE ORANGE
INTRACAVITARY TREATMENT OF SOFT TISSUE SARCOMAS IN DOGS USING CISPLATIN IN A BIODEGRADABLE POLYMER
Orthopaedic Oncology and Limb Salvage
FUNCTION AND QUALITY OF LIFE OUTCOMES IN A RANDOMIZED TRIAL COMPARING PRE-OPERATIVE vs POST-OPERATIVE RADIOTHERAPY IN EXTREMITY SOFT TISSUE SARCOMA
CRITICAL EVALUATION OF THE MIRELS RATING SYSTEM FOR IMPENDING PATHOLOGIC FEMUR FRACTURES
METASTATIC DISEASE AS A RISK FACTOR FOR ADVERSE EVENTS DURING CEMENTED LONG-STEM FEMORAL ARTHROPLASTY
OUTCOME OF PELVIC ALLOGRAFT TRANSPLANTATION
PREOPERATIVE CHEMOTHERAPY WITH DOSE-INTENSIVE ADRIAMYCIN (A) AND IFOSFAMIDE (I) FOR HIGH-RISK PRIMARY SOFT-TISSUE SARCOMAS (STS) OF EXTREMITY ORIGIN
DOXIL® / CAELYX® HAS ANTITUMOUR ACTIVITY IN ADVANCED SOFT TISSUE SARCOMA WITH REDUCED TOXICITY COMPARED TO DOXORUBICIN
A META-ANALYSIS (MA) OF RANDOMIZED TRIALS (RCT’s) OF DOXORUBICIN (DOX) ALONE VS DOXORUBICIN COMBINATION CHEMOTHERAPY (DOX-COMB) IN ADVANCED/METASTATIC ADULT SOFT TISSUE SARCOMA (ASTS))
PHASE I/II STUDY WITH THE MDR INHIBITORTM (BIRICODAR, VX-710) + DOXORUBICIN (DOX) IN ANTHRACYCLINE RESISTANT ADVANCED SOFT TISSUE SARCOMA (STS)
PHASE II STUDY ON GEMCITABINE IN ADVANCED TISSUE SARCOMAS OF THE ADULTS
FILGRASTIM SCHEDULE VARIATION: IMPACT ON HEMATOPOIETIC TOXICITY POST CHEMOTHERAPY. PRELIMINARY RESULTS
LONG-TERM OUTCOME OF PATIENTS WITH T1 HIGH-GRADE EXTREMITY SOFT TISSUE SARCOMAS: IMPORTANCE OF LONG-TERM FOLLOW-UP
THE IMPACT OF AN AGGRESSIVE LOCAL CONTROL POLICY AND OF ADJUVANT CHEMOTHERAPY IN PRIMARY PRESENTATION EXTREMITY ADULT SOFT-TISSUE SARCOMA IN SEQUENTIAL COHORTS OVER 20 YEARS
RECENT EXPERIENCE WITH SARCOMATOSIS: LOW VOLUME DISEASE PREDICTS FOR IMPROVED SURVIVAL
